Update on novel agents in renal cell carcinoma (Q37642798)

21 August 2017

1 reference

title

Update on novel agents in renal cell carcinoma (English)

1 reference

21 August 2017

Ila Tamaskar

1

1 reference

PubMed ID

19954293

21 August 2017

Roberto Pili

series ordinal

2

1 reference

21 August 2017

1 December 2009

1 reference

Expert Review of Anticancer Therapy

21 August 2017

1 reference

21 August 2017

9

1 reference

21 August 2017

12

1 reference

21 August 2017

1817-1827

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

21 August 2017

1 reference

The Heidelberg classification of renal cell tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

RAF antisense oligonucleotide as a tumor radiosensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Sequential sorafenib and sunitinib for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.157

21 January 2018

Identifiers

DOI

10.1586/ERA.09.157

1 reference

21 August 2017

1 reference

PubMed ID

19954293